Corporate Whistleblower Center Urges Pharmaceutical Insiders With Proof of Company's Involvement in Adulterated Drugs to Contact Them About Reward Program Information

Share Article

The Corporate Whistleblower Center is encouraging all pharmaceutical insiders with proof of company involvement in manufacturing or distributing adulterated drugs to contact them at 866-714-6466 for information about potential rewards. http://CorporateWhistleblowerCenter.Com

News Image
The whistleblower in the Ranbaxy case received $48.6 million from the settlement. For more information potential whistleblowers are welcome to contact the Corporate Whistleblower Center anytime at 866-714-6466

The Corporate Whistleblower Center says, "Rewards for whistleblowers in pharmaceutical companies can be staggering. According to a May 13th 2013 Department of Justice press release, Ranbaxy USA, a generic drug manufacturer and subsidiary of Ranbaxy Laboratories Limited in England, plead guilty and agreed to pay a $500 million fine for their alleged involvement in manufacturing and distributing adulterated drugs. Adulterated drugs are drugs that are manufactured, processed, or packaged in facilities that do not conform to current Good Manufacturing Practices. The FDA prohibits the introduction or delivery of these types of drugs."

The Corporate Whistleblower Center says, “The FDA holds pharmaceutical companies to the highest standards regarding the manufacture and distribution of prescription drugs, both name brand and generic. As we can see from the Ranbaxy case, fines and charges for allegedly violating these laws are significant. For whistleblowers, this means rewards are just as substantial. The whistleblower in the Ranbaxy case received $48.6 million from the settlement.”

The Corporate Whistleblower Center is urging pharmaceutical company insiders with proof of a company selling adulterated drugs to contact them anytime at 866-714-6466 for more information about a potential reward programs. All information is kept completely confidential. If the proof of wrongdoing is well documented, the Corporate Whistleblower Center will get the possible whistleblower to nations premier whistleblower attorneys, with the goal being the best possible reward. http://CorporateWhistleblowerCenter.Com

Simple rules for a whistleblower from the Corporate Whistleblower Center:

  • Do not go to the government first if you are a major whistleblower. The Corporate Whistleblower Center says, “Major whistleblowers frequently go to the federal government thinking they will help. It’s a huge mistake.”
  • Do not go to the news media with your whistleblower information. Public revelation of a whistleblower’s information could destroy any prospect for a reward.
  • Do not try to force a government contractor, or corporation to come clean to the government about their wrongdoing. The Corporate Whistleblower Center says, “Fraud is so rampant among federal contractors that any suggestion of exposure might result in an instant job termination, or harassment of the whistleblower. Come to us first, tell us what type of information you have, and if we think it’s sufficient, we will help find the right law firms to assist in advancing your information.”

The Corporate Whistleblower Center wants to emphasize there are high quality whistleblowers in every state including California, New York, Florida, Texas, Massachusetts, Maryland, Virginia, Ohio, Pennsylvania, Tennessee, North Carolina, Georgia, Alabama, Louisiana, Missouri, Michigan, Iowa, Indiana, Illinois, Wisconsin, Minnesota, North Dakota, Nebraska, Kansas, Colorado, Utah, New Mexico, Arizona, Nevada, Idaho, Oregon, Washington, and Alaska. Any type of insider, or employee, who possesses significant proof of their employer, or a government contractor defrauding the federal government is encouraged to contact to Corporate Whistleblower Center anytime at 866-714-6466, or they can contact the group via their web site at http://CorporateWhistleBlowerCenter.Com

For attribution purposes please review the United States Department of Justice Press release dated May 13th, 2013: http://www.justice.gov/opa/pr/2013/May/13-civ-542.html

Case number: United States v. Ranbaxy Laboratories, Ltd., et al. , Case No. JFM-12-250 (D. Md).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

M Thomas Martin
Visit website

Media